July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
MRI Screening for Adalimumab Therapy in Uveitis
Author Affiliations & Notes
  • Joshua Luis
    Moorfields Eye Hospital, United Kingdom
  • Priyanka Sanghi
    Moorfields Eye Hospital, United Kingdom
  • Edward Hindle
    Moorfields Eye Hospital, United Kingdom
  • Angela L Rees
    Moorfields Eye Hospital, United Kingdom
  • Mark C Westcott
    Moorfields Eye Hospital, United Kingdom
    Institute of Ophthalmology, United Kingdom
  • Footnotes
    Commercial Relationships   Joshua Luis, None; Priyanka Sanghi, None; Edward Hindle, None; Angela Rees, None; Mark Westcott, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 6111. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Joshua Luis, Priyanka Sanghi, Edward Hindle, Angela L Rees, Mark C Westcott; MRI Screening for Adalimumab Therapy in Uveitis. Invest. Ophthalmol. Vis. Sci. 2019;60(9):6111.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : The use of tumour necrosis factor-alpha (TNF-α) antagonists such as Adalimumab is becoming increasingly common in the management of uveitic syndromes which are refractory to first-line management. An important consideration when commencing this class of medication is the possibility of inducing demyelinating disease. In this study, we present the findings from a neuroimaging screening program for patients with uveitis prior to commencing Adalimumab.

Methods : Records from all patients seen at a specialist screening clinic for Adalimumab treatment in Moorfields Eye Hospital between 1st November 2017 and 1st November 2018 were analysed retrospectively. The aim of the screening was to elicit any contra-indications to commencing Adalimumab with relevant history-taking and examination. The screening protocol for performing an MRI included patients with a diagnosis of idiopathic intermediate uveitis (IIU) or typical symptoms of demyelinating disease such as paraesthesia and numbness. Patient demographics, underlying disease aetiology and the outcomes of the MRI scans were recorded and analysed.

Results : Ninety-two cases were identified during this period, three cases did not proceed to Adalimumab treatment due to clinical reasons and were therefore excluded from analysis. Eighty-nine cases were analysed, 56 of these did not require MRI scanning according to our screening protocol, recent scans were available in 19 cases as a part of their prior clinical management, and 14 scans were performed as a direct result of screening. MRIs strongly suggestive of demyelination (MRSSD) were found in 4 out of 14 (29%) scans, a further 4 scans showed non-specific white matter lesions, and the remaining 6 scans showed no abnormalities. MRSSD cases ranged between 25 and 55 years of age with a female majority (3/4), all cases had an underlying diagnosis of bilateral IIU and were predominantly symptomatic (3/4).

Conclusions : TNF-α antagonist induced demyelination is a concern in Adalimumab use, which necessitates appropriate neurological referral and reconsideration of immunosuppressive in high-risk cases. Within this study cohort, our current screening protocol shows a high yield of identifying pre-existing MRI changes. Bilateral IIU and the presence of neurological symptoms both appear to be positive predictors.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.